Reclaim the moments that move you
BREATHE THEM IN
WITH TYVASO FOR PH-ILD
TYVASO and TYVASO DPI are approved for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability.
Hear how TYVASO helped Catherine be more active in her day-to-day life.
If you have been prescribed TYVASO for PH-ILD, you can talk to a Virtual Patient Educator* to learn more and receive support through the Archways program.
United Therapeutics and the Archways program do not provide medical advice. You are advised to consult with your healthcare provider with any specific questions or concerns about your treatment.
With the TYVASO Co-Pay Assistance Program, most eligible patients pay as little as a $0 co-pay for each prescription of TYVASO or TYVASO DPI.